$NKTR
NEKTAR THERAPEUTICS

2024 Q2 Form 10-Q Financial Statement

#000095017024057312 Filed on May 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $23.49M $21.64M $23.89M
YoY Change 14.59% 0.21% 8.45%
Cost Of Revenue $9.740M $8.534M $7.283M
YoY Change 39.26% 20.88% 16.85%
Gross Profit $13.75M $13.11M $16.60M
YoY Change 1.81% -9.83% 5.14%
Gross Profit Margin 58.53% 60.56% 69.51%
Selling, General & Admin $20.51M $20.15M $17.32M
YoY Change 14.78% -4.42% -21.05%
% of Gross Profit 149.17% 153.75% 104.32%
Research & Development $29.72M $27.41M $29.94M
YoY Change 0.14% -10.05% -13.81%
% of Gross Profit 216.19% 209.14% 180.35%
Depreciation & Amortization $1.459M $1.607M $1.615M
YoY Change -32.64% -30.19% -49.25%
% of Gross Profit 10.61% 12.26% 9.73%
Operating Expenses $29.72M $27.41M $45.96M
YoY Change 0.14% -10.05% -18.91%
Operating Profit -$49.77M -$35.43M -$29.36M
YoY Change -1.63% -73.7% -28.2%
Interest Expense -$2.507M -$1.311M -$2.350M
YoY Change 339.82% -44.71% -42.33%
% of Operating Profit
Other Income/Expense, Net -$2.543M -$1.410M -$6.247M
YoY Change 346.14% -40.53%
Pretax Income -$52.32M -$36.84M -$42.11M
YoY Change 2.24% -73.13% -25.53%
Income Tax $46.00K -$35.00K -$29.00K
% Of Pretax Income
Net Earnings -$52.36M -$36.80M -$42.08M
YoY Change 2.43% -73.14% -29.5%
Net Earnings / Revenue -222.93% -170.07% -176.17%
Basic Earnings Per Share -$0.25 -$0.19
Diluted Earnings Per Share -$0.25 -$0.19 -$0.22
COMMON SHARES
Basic Shares Outstanding 183.6M 183.6M 190.8M
Diluted Shares Outstanding 208.8M 194.7M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $271.2M $289.2M $303.6M
YoY Change -33.75% -36.69% -39.88%
Cash & Equivalents $27.94M $48.64M $35.28M
Short-Term Investments $243.3M $240.6M $268.3M
Other Short-Term Assets $8.292M $10.74M $9.779M
YoY Change -13.64% -2.42% -38.14%
Inventory $14.47M $16.24M $16.10M
Prepaid Expenses
Receivables $1.196M $3.617M $1.205M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $295.2M $319.8M $330.7M
YoY Change -33.07% -34.87% -39.43%
LONG-TERM ASSETS
Property, Plant & Equipment $15.19M $17.48M $18.86M
YoY Change -32.66% -35.48% -41.89%
Goodwill $0.00
YoY Change -100.0%
Intangibles
YoY Change
Long-Term Investments $19.41M $36.78M $25.83M
YoY Change
Other Assets $4.314M $4.656M $4.644M
YoY Change 161.14% 231.15% 106.86%
Total Long-Term Assets $48.15M $76.18M $67.33M
YoY Change -9.54% 7.78% -59.1%
TOTAL ASSETS
Total Short-Term Assets $295.2M $319.8M $330.7M
Total Long-Term Assets $48.15M $76.18M $67.33M
Total Assets $343.3M $396.0M $398.0M
YoY Change -30.54% -29.5% -43.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.475M $8.757M $9.848M
YoY Change 147.23% 136.93% -24.13%
Accrued Expenses $29.51M $24.28M $22.16M
YoY Change 1.28% -35.09% -59.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $57.33M $52.41M $51.27M
YoY Change 13.08% -12.48% -24.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.051M $4.334M $4.635M
YoY Change 56.3% -33.11% -38.62%
Total Long-Term Liabilities $8.051M $4.334M $4.635M
YoY Change 56.3% -33.11% -38.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $57.33M $52.41M $51.27M
Total Long-Term Liabilities $8.051M $4.334M $4.635M
Total Liabilities $263.6M $269.3M $267.0M
YoY Change -11.33% -16.07% -22.36%
SHAREHOLDERS EQUITY
Retained Earnings -$3.566B -$3.514B -$3.477B
YoY Change 5.22% 5.27% 8.62%
Common Stock $3.650B $3.644B $3.608B
YoY Change 1.58% 1.66% 0.93%
Preferred Stock
YoY Change
Treasury Stock (at cost) $3.000M $3.000M $0.00
YoY Change
Treasury Stock Shares
Shareholders Equity $79.69M $126.7M $131.0M
YoY Change
Total Liabilities & Shareholders Equity $343.3M $396.0M $398.0M
YoY Change -30.54% -29.5% -43.99%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$52.36M -$36.80M -$42.08M
YoY Change 2.43% -73.14% -29.5%
Depreciation, Depletion And Amortization $1.459M $1.607M $1.615M
YoY Change -32.64% -30.19% -49.25%
Cash From Operating Activities -$37.70M -$47.89M -$47.01M
YoY Change -26.82% -7.76% -18.54%
INVESTING ACTIVITIES
Capital Expenditures $186.0K $157.0K $265.0K
YoY Change 14.81% -63.74% -48.24%
Acquisitions
YoY Change
Other Investing Activities $17.17M $19.42M $17.63M
YoY Change -32.23% -52.68% -56.5%
Cash From Investing Activities $16.98M $19.26M $17.36M
YoY Change -32.53% -52.56% -56.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.00K 42.00M 30.00K
YoY Change 5.56% -70.87%
NET CHANGE
Cash From Operating Activities -37.70M -47.89M -47.01M
Cash From Investing Activities 16.98M 19.26M 17.36M
Cash From Financing Activities 19.00K 42.00M 30.00K
Net Change In Cash -20.70M 13.37M -29.61M
YoY Change -21.39% -218.57% 68.38%
FREE CASH FLOW
Cash From Operating Activities -$37.70M -$47.89M -$47.01M
Capital Expenditures $186.0K $157.0K $265.0K
Free Cash Flow -$37.89M -$48.05M -$47.27M
YoY Change -26.69% -8.22% -18.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000906709
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
0-24006
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3134940
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
455 Mission Bay Boulevard South
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
CY2024Q1 dei City Area Code
CityAreaCode
415
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
482-5300
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2024Q1 dei Trading Symbol
TradingSymbol
NKTR
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
183624620
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48642000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35277000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
240596000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
268339000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3617000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1205000
CY2024Q1 us-gaap Inventory Net
InventoryNet
16238000
CY2023Q4 us-gaap Inventory Net
InventoryNet
16101000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
10743000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
9779000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
319836000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
330701000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
36778000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
25825000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17475000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18856000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17267000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18007000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4656000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4644000
CY2024Q1 us-gaap Assets
Assets
396012000
CY2023Q4 us-gaap Assets
Assets
398033000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
8757000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9848000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24281000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22162000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19368000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19259000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
52406000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51269000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
94710000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
98517000
CY2024Q1 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
117857000
CY2023Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
112625000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4334000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4635000
CY2024Q1 us-gaap Liabilities
Liabilities
269307000
CY2023Q4 us-gaap Liabilities
Liabilities
267046000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0
CY2023Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
191909000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
191384000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
183624000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
191384000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
19000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3644140000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3608137000
CY2024Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
8285000
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0
CY2024Q1 us-gaap Treasury Stock Value
TreasuryStockValue
3000000
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-403000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3514051000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3477249000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
126705000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
130987000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
396012000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
398033000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21639000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21594000
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8534000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7060000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27408000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30469000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20149000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21081000
CY2024Q1 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
975000
CY2024Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
3000000
CY2024Q1 nktr Issuance Of Prefunded Warrant
IssuanceOfPrefundedWarrant
30000000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37285000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
126705000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-36802000
CY2023Q1 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
21193000
CY2024Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
57066000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
156304000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-35427000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-134710000
CY2024Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
5531000
CY2023Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
6405000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
4220000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
4335000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-99000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-301000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1410000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2371000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36837000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-137081000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-35000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-63000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-36802000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-137018000
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
194746000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
194746000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
188875000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
188875000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-36802000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-137018000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-475000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1087000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
139000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-483000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1226000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37285000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-135792000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
366638000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10019000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-135792000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
240865000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
130987000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6000000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-137018000
CY2024Q1 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
15508000
CY2023Q1 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
16861000
CY2024Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
5531000
CY2023Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
6405000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6000000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10019000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1607000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2302000
CY2024Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-38000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1812000
CY2024Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13200000
CY2024Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000
CY2024Q1 nktr Provision For Inventory Obsolescence
ProvisionForInventoryObsolescence
1006000
CY2023Q1 nktr Provision For Inventory Obsolescence
ProvisionForInventoryObsolescence
952000
CY2024Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3063000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3129000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2412000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2986000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1143000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1985000
CY2024Q1 nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
2958000
CY2023Q1 nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
1786000
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
976000
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-5591000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-988000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8920000
CY2024Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1856000
CY2023Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1640000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47888000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51915000
CY2024Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
105059000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
107012000
CY2024Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
124474000
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
148043000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
157000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
433000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19258000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
40598000
CY2024Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
3000
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0
CY2024Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
30000000
CY2023Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
CY2024Q1 nktr Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
15000000
CY2023Q1 nktr Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
0
CY2024Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3000000
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42003000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-8000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13365000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11272000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35277000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88227000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48642000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76955000
CY2024Q1 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
326000000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></p>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Concentrations</span></p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customers are primarily pharmaceutical companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. We generally do not require collateral from our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customers. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We perform a regular review of our customers’ credit risk and payment histories, including payments made after period end. Historically, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t experienced credit losses from our accounts receivable. We have not recorded reserves for credit losses for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2024 and 2023, nor have recorded such an allowance as of March 31, 2024 or December 31, 2023.</span></p><p style="text-indent:5.84%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer’s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></p>
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48642000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35277000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
240596000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
268339000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
36778000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
25825000
CY2024Q1 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
326016000
CY2023Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
329441000
CY2024Q1 us-gaap Cash
Cash
5427000
CY2023Q4 us-gaap Cash
Cash
17843000
CY2024Q1 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
326016000
CY2023Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
329441000
CY2024Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1936000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1861000
CY2024Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
9962000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
12880000
CY2024Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4340000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1360000
CY2024Q1 us-gaap Inventory Net
InventoryNet
16238000
CY2023Q4 us-gaap Inventory Net
InventoryNet
16101000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
10743000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
9779000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7384000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5553000
CY2024Q1 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
4233000
CY2023Q4 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
4321000
CY2024Q1 nktr Liability To Collaboration Partners Current
LiabilityToCollaborationPartnersCurrent
1310000
CY2023Q4 nktr Liability To Collaboration Partners Current
LiabilityToCollaborationPartnersCurrent
2678000
CY2024Q1 nktr Accrued Contract Termination Costs Current
AccruedContractTerminationCostsCurrent
3043000
CY2023Q4 nktr Accrued Contract Termination Costs Current
AccruedContractTerminationCostsCurrent
3020000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8311000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6590000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24281000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22162000
CY2023Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
112625000
CY2024Q1 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
15508000
CY2024Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
5531000
CY2024Q1 nktr Liabilities On Sale Of Future Royalties Amortized Transaction Costs
LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts
209000
CY2024Q1 nktr Proceeds From Amendment Related To Sales Of Future Royalties Net
ProceedsFromAmendmentRelatedToSalesOfFutureRoyaltiesNet
15000000
CY2024Q1 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
117857000
CY2024Q1 us-gaap Litigation Reserve
LitigationReserve
0
CY2023Q4 us-gaap Litigation Reserve
LitigationReserve
0
CY2024Q1 us-gaap Business Exit Costs1
BusinessExitCosts1
0
CY2023Q1 us-gaap Business Exit Costs1
BusinessExitCosts1
1598000
CY2024Q1 us-gaap Severance Costs1
SeveranceCosts1
0
CY2023Q1 us-gaap Severance Costs1
SeveranceCosts1
5483000
CY2024Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13200000
CY2024Q1 us-gaap Loss On Contract Termination
LossOnContractTermination
975000
CY2023Q1 us-gaap Loss On Contract Termination
LossOnContractTermination
912000
CY2024Q1 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
975000
CY2023Q1 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
21193000
CY2023Q1 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
11500000
CY2023Q1 nktr Impairment Long Lived Asset Held For Use Other
ImpairmentLongLivedAssetHeldForUseOther
1700000
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13200000
CY2024Q1 nktr Impairment Of Remaining Long Lived Asset Held For Use
ImpairmentOfRemainingLongLivedAssetHeldForUse
0
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76500000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6000000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10019000
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Trd Arr Ind Name
TrdArrIndName
Robert Chess
CY2024Q1 ecd Trd Arr Ind Title
TrdArrIndTitle
Director
CY2024Q1 ecd Trd Arr Adoption Date
TrdArrAdoptionDate
March 14, 2024
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2024Q1 ecd Trd Arr Securities Agg Avail Amt
TrdArrSecuritiesAggAvailAmt
19500000
CY2024Q1 nktr Trd Arr Expiration Date
TrdArrExpirationDate
July 15, 2024

Files In Submission

Name View Source Status
0000950170-24-057312-index-headers.html Edgar Link pending
0000950170-24-057312-index.html Edgar Link pending
0000950170-24-057312.txt Edgar Link pending
0000950170-24-057312-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nktr-20240331.htm Edgar Link pending
nktr-20240331.xsd Edgar Link pending
nktr-ex10_16.htm Edgar Link pending
nktr-ex31_1.htm Edgar Link pending
nktr-ex31_2.htm Edgar Link pending
nktr-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nktr-20240331_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending